FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2910585512> ?p ?o ?g. }

• W2910585512 endingPage "4660" @default.
• W2910585512 startingPage "4660" @default.
• W2910585512 abstract "Abstract Background: Although matched related donors (MRD) are the preferred source of stem cells for allogeneic hematopoietic cell transplantation, umbilical cord blood (UCB) is a well-established donor source in patients without a MRD or matched unrelated donor (MUD). Prior studies (Eapen et al, Lancet Oncology 2010; Rocha et al, NEJM 2004) have shown similar overall survival and relapse rates after umbilical cord blood transplant (UCBT), and our group (Gutman et al, BMT 2016) has shown lower chronic graft-versus-host-disease (GVHD) when compared to MUD transplant. Based on these data, our preferred donor source is MRD followed by UCB. Here, we evaluate our data comparing transplant outcomes in UCBT recipients versus MRD recipients. Methods: We compared outcomes in all consecutive adult patients undergoing first MRD transplant versus first double UCBT from January 2010 to December 2017. Patient selection, graft-versus-host disease prophylaxis and transfusions were per institutional standards. Graft-versus-host-disease free, relapse free survival (GRFS) was defined by events that includedgrade 3-4 acute GVHD, moderate to severe chronic GVHD, relapse or any death. Results: Of the 296 patients studied, 187 underwent UCBT and 109 received MRD transplant. Graft failure occurred in 6 (3%) UCBT recipients (5 of whom received reduced intensity conditioning) and did not occur in any MRD transplant recipients. While the incidence of grade 2-4 acute GVHD was higher in UCBT recipients (p= 0.006), grade 3-4 acute GVHD was comparable (p= 0.36) between the two groups. Any chronic GVHD (p= 0.0000001) and moderate to severe chronic GVHD (p= 0.00011) was significantly higher in MRD transplant recipients (figure 1a and 1b). There were significantly lower disease relapses in UCBT recipients (n= 51, 27% versus n= 46, 42%; p= 0.0036) compared to MRD transplant recipients. Transplant related mortality was higher in UCBT recipients (n= 33, 42% versus n= 11, 23% in MRD transplant recipients; p= 0.03). There was no difference in GRFS (p=0.15, figure 1c) and overall survival (OS) in the 2 study cohorts (p=0.31, figure 1d). Conclusions: UCBT recipients as compared to MRD recipients had lower chronic GVHD and lower relapse rates with no difference in OS and the composite endpoint of GRFS. Based on these results, UCB remains an appropriate alternative donor source for hematopoietic cell transplantation and might result in improved quality of life by virtue of lower incidence of chronic GVHD in long-term transplant survivors. Disclosures Haverkos: Viracta Therapeutics: Membership on an entity's Board of Directors or advisory committees. Pollyea:Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Agios: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Gilead: Consultancy; Celgene: Membership on an entity's Board of Directors or advisory committees; Argenx: Consultancy, Membership on an entity's Board of Directors or advisory committees; Curis: Membership on an entity's Board of Directors or advisory committees; Karyopharm: Membership on an entity's Board of Directors or advisory committees; Celyad: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Research Funding. Kamdar:Seattle Genetics: Membership on an entity's Board of Directors or advisory committees. Mark:Janssen, Takeda, Celgene, Amgen: Consultancy; BMS, Celgene: Research Funding; Celgene: Honoraria." @default.
• W2910585512 created "2019-01-25" @default.
• W2910585512 creator A5000537427 @default.
• W2910585512 creator A5004461149 @default.
• W2910585512 creator A5012012199 @default.
• W2910585512 creator A5032549755 @default.
• W2910585512 creator A5033803571 @default.
• W2910585512 creator A5041615072 @default.
• W2910585512 creator A5042701986 @default.
• W2910585512 creator A5046962135 @default.
• W2910585512 creator A5056839401 @default.
• W2910585512 creator A5087902006 @default.
• W2910585512 date "2018-11-29" @default.
• W2910585512 modified "2023-10-16" @default.
• W2910585512 title "Chronic Graft Versus Host Disease Burden and Relapse Rates Are Lower with Comparable Overall Survival and Graft Versus Host Disease Free, Relapse Free Survival Following Adult Umbilical Cord Blood Compared to Matched Sibling Peripheral Blood Stem Cell Transplantation" @default.
• W2910585512 doi "https://doi.org/10.1182/blood-2018-99-119690" @default.
• W2910585512 hasPublicationYear "2018" @default.
• W2910585512 type Work @default.
• W2910585512 sameAs 2910585512 @default.
• W2910585512 citedByCount "0" @default.
• W2910585512 crossrefType "journal-article" @default.
• W2910585512 hasAuthorship W2910585512A5000537427 @default.
• W2910585512 hasAuthorship W2910585512A5004461149 @default.
• W2910585512 hasAuthorship W2910585512A5012012199 @default.
• W2910585512 hasAuthorship W2910585512A5032549755 @default.
• W2910585512 hasAuthorship W2910585512A5033803571 @default.
• W2910585512 hasAuthorship W2910585512A5041615072 @default.
• W2910585512 hasAuthorship W2910585512A5042701986 @default.
• W2910585512 hasAuthorship W2910585512A5046962135 @default.
• W2910585512 hasAuthorship W2910585512A5056839401 @default.
• W2910585512 hasAuthorship W2910585512A5087902006 @default.
• W2910585512 hasConcept C126322002 @default.
• W2910585512 hasConcept C141071460 @default.
• W2910585512 hasConcept C143998085 @default.
• W2910585512 hasConcept C203014093 @default.
• W2910585512 hasConcept C2776955114 @default.
• W2910585512 hasConcept C2777408962 @default.
• W2910585512 hasConcept C2779972918 @default.
• W2910585512 hasConcept C2908824208 @default.
• W2910585512 hasConcept C2911091166 @default.
• W2910585512 hasConcept C71924100 @default.
• W2910585512 hasConcept C90924648 @default.
• W2910585512 hasConceptScore W2910585512C126322002 @default.
• W2910585512 hasConceptScore W2910585512C141071460 @default.
• W2910585512 hasConceptScore W2910585512C143998085 @default.
• W2910585512 hasConceptScore W2910585512C203014093 @default.
• W2910585512 hasConceptScore W2910585512C2776955114 @default.
• W2910585512 hasConceptScore W2910585512C2777408962 @default.
• W2910585512 hasConceptScore W2910585512C2779972918 @default.
• W2910585512 hasConceptScore W2910585512C2908824208 @default.
• W2910585512 hasConceptScore W2910585512C2911091166 @default.
• W2910585512 hasConceptScore W2910585512C71924100 @default.
• W2910585512 hasConceptScore W2910585512C90924648 @default.
• W2910585512 hasIssue "Supplement 1" @default.
• W2910585512 hasLocation W29105855121 @default.
• W2910585512 hasOpenAccess W2910585512 @default.
• W2910585512 hasPrimaryLocation W29105855121 @default.
• W2910585512 hasRelatedWork W2318530450 @default.
• W2910585512 hasRelatedWork W2359804617 @default.
• W2910585512 hasRelatedWork W2365848850 @default.
• W2910585512 hasRelatedWork W2392641532 @default.
• W2910585512 hasRelatedWork W2442220036 @default.
• W2910585512 hasRelatedWork W2590912865 @default.
• W2910585512 hasRelatedWork W265735815 @default.
• W2910585512 hasRelatedWork W3029666843 @default.
• W2910585512 hasRelatedWork W4247148241 @default.
• W2910585512 hasRelatedWork W2114487924 @default.
• W2910585512 hasVolume "132" @default.
• W2910585512 isParatext "false" @default.
• W2910585512 isRetracted "false" @default.
• W2910585512 magId "2910585512" @default.
• W2910585512 workType "article" @default.